RU93016671A - IMMUNODULATOR - Google Patents

IMMUNODULATOR

Info

Publication number
RU93016671A
RU93016671A RU93016671/14A RU93016671A RU93016671A RU 93016671 A RU93016671 A RU 93016671A RU 93016671/14 A RU93016671/14 A RU 93016671/14A RU 93016671 A RU93016671 A RU 93016671A RU 93016671 A RU93016671 A RU 93016671A
Authority
RU
Russia
Prior art keywords
impaired
diseases associated
immunity
lymphotoxic
lymphotropic
Prior art date
Application number
RU93016671/14A
Other languages
Russian (ru)
Other versions
RU2108100C1 (en
Inventor
В.А. Козлов
О.Т. Кудаева
О.П. Колесникова
М.Н. Тузова
В.С. Ширинский
А.Н. Мирскова
Г.Г. Левковская
С.Ф. Сухенко
С.Ф. Кирикова
М.Г. Воронков
Original Assignee
Институт клинической иммунологии СО РАМН
Filing date
Publication date
Application filed by Институт клинической иммунологии СО РАМН filed Critical Институт клинической иммунологии СО РАМН
Priority to RU93016671A priority Critical patent/RU2108100C1/en
Priority claimed from RU93016671A external-priority patent/RU2108100C1/en
Publication of RU93016671A publication Critical patent/RU93016671A/en
Application granted granted Critical
Publication of RU2108100C1 publication Critical patent/RU2108100C1/en

Links

Claims (1)

Иммуномодулятор может быть использован в медицине для профилактики и лечения заболеваний, связанных с нарушением иммунитета. Получаемый на основе доступного химического сырья синтетическим путем с высоким выходом водорастворимый, высокоактивный, нетоксичный препарат - трис - (2-гидроксиэтил) - аммоний индолил-3-тиоцетат - обладает иммуномодулирующими свойствами; выраженное Т-лимфотропное действие, наряду с отсутствием лимфотоксических свойств, позволяет расширить арсенал иммуномодулирующих средств для целенаправленной коррекции заболеваний, связанных с нарушением Т-клеточного звена иммунитета.An immunomodulator can be used in medicine for the prevention and treatment of diseases associated with impaired immunity. The water-soluble, highly active, non-toxic drug, tris- (2-hydroxyethyl) - ammonium indolyl-3-thioacetate, obtained on the basis of the available chemical raw materials in a synthetic way; A pronounced T-lymphotropic effect, along with the absence of lymphotoxic properties, makes it possible to expand the arsenal of immunomodulatory agents for the targeted correction of diseases associated with impaired T-cell immunity.
RU93016671A 1993-03-31 1993-03-31 Immunomodulating agent RU2108100C1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
RU93016671A RU2108100C1 (en) 1993-03-31 1993-03-31 Immunomodulating agent

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
RU93016671A RU2108100C1 (en) 1993-03-31 1993-03-31 Immunomodulating agent

Publications (2)

Publication Number Publication Date
RU93016671A true RU93016671A (en) 1995-05-10
RU2108100C1 RU2108100C1 (en) 1998-04-10

Family

ID=20139569

Family Applications (1)

Application Number Title Priority Date Filing Date
RU93016671A RU2108100C1 (en) 1993-03-31 1993-03-31 Immunomodulating agent

Country Status (1)

Country Link
RU (1) RU2108100C1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007073231A1 (en) * 2005-12-23 2007-06-28 Victor Lvovoch Limonov Agent for treating tumoral diseases, a method for the production thereof and a method for treating tumoral diseases
RU2642778C2 (en) * 2016-04-04 2018-01-26 Федеральное государственное бюджетное учреждение науки Иркутский институт химии им. А.Е. Фаворского Сибирского отделения Российской академии наук Method for obtaining of 1-r-indole-3-ylsulfanylacetates of (2-hydroxyethyl)ammonium

Similar Documents

Publication Publication Date Title
NO954996D0 (en) Use of nona and decapeptides for the manufacture of a medicament for the treatment of AIDS
BG101118A (en) Therapeutical compounds
ES2092890T3 (en) APPLICATION OF RILUZOLE IN THE TREATMENT OF PARKINSON'S DISEASE AND PARKINSON'S SYNDROMES.
ES2058892T3 (en) USE OF OMEPRAZOLE AS ANTIMICROBIAL AGENT.
LU90856I2 (en) Uprima - apomorphine hydrochloride and its pharmaceutically acceptable derivatives
MX9305248A (en) DIARILPIPERAZINOACETAMIDA COMPOUNDS.
NO922936D0 (en) PREPARATION OF FATIC ACID MEDICINES
SE9201930D0 (en) GASTRIC ANTIBACTERIAL TREATMENT
ES2177024T3 (en) EMPLOYMENT OF THE FANQUINOMA FOR THE TREATMENT OF ALZHEIMER'S DISEASE.
MX9707642A (en) Pharmaceutical agents for the treatment of alzheimer's disease.
RU93016671A (en) IMMUNODULATOR
BR0116653A (en) Medicinal product containing a polyamine as active substance
EE03514B1 (en) A combination of compounds for the treatment of HIV infection or AIDS, its use and a pharmaceutical composition
AU2880595A (en) Use of pharmaceutical agents for restoring, alleviation, or treatment of immunodeficiency, including the alleviation or treatment of the immune dysfunction related to infection with human immunodeficiency viruses (hiv) or related viruses
EA199900963A1 (en) MEDICAL FORMS OF SERTRALIN IN THE FORM OF A SOLUTION CONCLUDED IN GELATINIC CAPSULES
AU5061090A (en) Aids therapy
ES2049711T1 (en) USE OF BUCILAMINE FOR THE MANUFACTURE OF A MEDICINAL PRODUCT FOR THE TREATMENT OF CYSTINURIA.
KR960003718A (en) Use of Ifenprodil and its Diastereomers for the Preparation of Medicines Useful for the Treatment of Peripheral and Central Neurodegenerative Diseases
HK1011527A1 (en) Use of allylamine derivatives such as terbinafine, in the manufacture of a medicament for the treatment of helicobacter pylori infection of associated diseases
DK0703781T3 (en) Use of Efaroxan and its Derivatives for the Preparation of a Drug to Treat Parkinson's Disease
ES1034986Y (en) APPARATUS FOR THE TREATMENT OF THE HUMAN BODY.
RU93030389A (en) MEANS RESTORING THE FUNCTION OF THE MESH EYE
GB9209599D0 (en) Novel therapy for the treatment of parkinsons disease
NO304011B1 (en) Use of atipamezole in the manufacture of a medicament for the treatment of men's impotence
ATE90565T1 (en) TREATMENT OF SHOCK WITH CYCLODEXTRIN AND ITS DERIVATIVES.